scholarly journals Absence of Wharton’s Jelly at the Abdominal Site of the Umbilical Cord Insertion. Rare Case Report and Review of the Literature

Medicina ◽  
2021 ◽  
Vol 57 (11) ◽  
pp. 1268
Author(s):  
Radu Botezatu ◽  
Sandra Raduteanu ◽  
Anca Marina Ciobanu ◽  
Nicolae Gica ◽  
Gheorghe Peltecu ◽  
...  

Wharton’s jelly is a specialized connective tissue surrounding and protecting umbilical cord vessels. In its absence, the vessels are exposed to the risk of compression or rupture. Because the condition is very rare and there are no available antepartum investigation methods for diagnosis, these cases are usually discovered after delivery, frequently after in utero fetal demise. We report the fortunate case of a 29-year-old nulliparous woman, with an uncomplicated pregnancy, admitted at 39 weeks in labor where a persistently abnormal cardiotocographic trace led to delivery by cesarean section of a healthy 3500 g newborn. After delivery, a Wharton’s jelly anomaly was identified at the abdominal umbilical insertion (umbilical cord vessels, approximately 1 cm in length, were completely uncovered by Wharton’s jelly), which required surgical thread elective ligation. In the presence of a persistently abnormal CTG trace, in a pregnancy with no clinical settings suggestive of either chronic or acute fetal hypoxemia, the absence of Wharton’s jelly should be taken into consideration in the differential diagnosis.

2021 ◽  
Vol 11 (7) ◽  
Author(s):  
Zhao Ting ◽  
Yan Zhi‐xin ◽  
Tan You‐wen ◽  
Yang Fu‐ji ◽  
Sun Hui ◽  
...  

2020 ◽  
Vol 13 (11) ◽  
pp. e237222
Author(s):  
Sarah J Murphy ◽  
Nikita Deegan ◽  
Bobby D O'Leary ◽  
Peter McParland

Wharton’s jelly is a specialised tissue which surrounds the vasculature within the fetal umbilical cord. We present the case of a 42-year-old woman who gave birth to a female infant via emergency caesarean section. At the time of delivery, absence of Wharton’s jelly was noted. This finding was confirmed by histological examination. Emergency caesarean section was necessitated due to a fetal bradycardia, and of note, the patient had presented twice prior to this with reduced fetal movements.


2021 ◽  
Vol 1 (1) ◽  
Author(s):  
Irene Carreras‐Sánchez ◽  
Alba López‐Fernández ◽  
Raquel Rojas‐Márquez ◽  
Roberto Vélez ◽  
Màrius Aguirre ◽  
...  

2019 ◽  
Vol 508 (4) ◽  
pp. 1149-1154
Author(s):  
José Romo-Yáñez ◽  
Mauricio Domínguez-Castro ◽  
Josiff S. Flores-Reyes ◽  
Higinio Estrada-Juárez ◽  
Ismael Mancilla-Herrera ◽  
...  

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Ahui Song ◽  
Jingjing Wang ◽  
Yan Tong ◽  
Junyan Fang ◽  
Yi Zhang ◽  
...  

Abstract Background Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) from the human umbilical cord have been studied extensively due to their immunomodulatory functions. Large-conductance Ca2+-activated K+ (BKCa channels) channels are involved in many inflammatory responses, but their involvement in the anti-inflammatory activity of WJ-MSCs is unknown. The underlying molecular mechanism, through which BKCa channels mediate the immunomodulation of WJ-MSC, which may include changes in exosomes proteomics, has not yet been clarified. Methods Alizarin staining, Oil Red O staining, and flow cytometry were used to identify WJ-MSCs, which were isolated from human umbilical cord Wharton’s jelly. BKCa channels were detected in WJ-MSCs using western blotting, real-time polymerase chain reaction (real-time PCR), and electrophysiology, and cytokine expression was examined using real-time PCR and enzyme-linked immunosorbent assays (ELISAs). Exosomes were characterized using transmission electron microscopy and nanoparticle tracking analysis. Proteomics analysis was performed to explore exosomal proteomic profiles. Results The cells derived from human umbilical cord Wharton’s jelly were identified as MSCs. BKCa channels were detected in the isolated WJ-MSCs, and the expression of these channels increased after lipopolysaccharide (LPS) stimulation. BKCa channels blockade in LPS-treated WJ-MSCs induced apoptosis and decreased interleukin-6 (IL-6) expression. Furthermore, THP-1 cells (human monocytic cell line) stimulated with LPS/interferon gamma (IFN-γ) produced more anti-inflammatory cytokines after treatment with exosomes derived from BKCa channel-knockdown WJ-MSCs (si-exo). We also observed altered expression of mitochondrial ATP synthase alpha subunit (ATP5A1), filamin B, and other proteins in si-exo, which might increase the anti-inflammatory activity of macrophages. Conclusions Our study described the functional expression of BKCa channels in WJ-MSCs, and BKCa channels regulated the immunomodulatory properties of WJ-MSCs by affecting the exosomal protein profiles during the inflammatory response.


PEDIATRICS ◽  
1970 ◽  
Vol 45 (1) ◽  
pp. 154-155
Author(s):  
H. Ekert

I am forced to comment on the far-reaching deductions drawn from the article by Dr. E. Richard Steihm and Dallas V. Clatanoff.1 Collection of blood from the cut surface of the umbilical cord invariably involves contamination of the blood with mucopolysaccharides of Wharton's jelly. These substances have a similar chemical structure to heparin and, like heparin, they exert a strong anti-thrombin effect. This can readily be confirmed by comparing the thrombin times of cord blood and blood obtained by venipuncture.


2020 ◽  
Author(s):  
Ashim Gupta ◽  
Hugo C. Rodriguez ◽  
Kristin Delfino ◽  
Howard J. Levy ◽  
Saadiq F. El-Amin III ◽  
...  

Abstract Background Erectile Dysfunction (ED) affects a significant portion of the U.S. population and causes negative psychological burdens that affects men and their partner’s quality of life and satisfaction. Extracorporeal shock therapy (ESWT) utilizing focused ESWT (fESWT) and radial ESWT (rESWT) in Low-intensity shock wave therapy (LSIWT) has been used to treat ED with some success. Wharton’s Jelly (WJ) is a biologic substance with large amounts of stem cells, growth factors, cytokines and extracellular components. The use of simultaneous fESWT and rESWT (DualStim Therapy) combined with WJ have potential uses in ED that may have advantages over current treatments. Methods A randomized, single-blinded, controlled clinical trial will be conducted to evaluate the efficacy and safety of DualStim Therapy and ICIs of WJ in moderate to severe ED. A total of 60 patients with moderate to severe ED will be enrolled and treated with DualStim Therapy with intracavernosal injection (ICIs) of WJ or saline for a period of 7 weeks. The International Index of Erectile Function – Erectile Function (IIEF-EF) score will be used to gauge the treatment related changes in relation to the subject’s baseline. The scores will be recorded at baseline and compared to follow-ups 1,3 and 6 months post-treatment. Any Adverse events (AEs) or severe AEs will be recorded in the corresponding case report forms (CRFs). Sexual Encounter Profile (SEP), as well as the Global Assessment Questionnaire (GAQ) and the Erection Hardness Score (EHS) will be used to determine the sexual activity improvement from baseline leading to optimal penetration at follow-ups 1,3 and 6 months post-treatment.Discussion This clinical trial is a feasibility study to determine the immediate and short-term efficacy of DualStim Therapy, with and without ICIs of formulated umbilical cord-derived WJ to improve and/or restore erectile function in patients with moderate to severe ED. This study will also provide insight into the safety and efficacy of WJ. We anticipate clinically significant improvement in patients suffering from moderate and severe ED treated with DualStim therapy with WJ compared to their baseline and DualStim with saline.Trial registration Registered on ClinicalTrials.gov; the trial number is NCT04424394


Sign in / Sign up

Export Citation Format

Share Document